Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Enterprise Financial Services Corp
EFSC
$2.4B
| $7.21M | ﹤0.01% |
133,230
+64
| +0% | +$3.61K |
|
427
Krystal Biotech
KRYS
$10.1B
| $7.18M | ﹤0.01% |
27,784
+23,998
| +634% | +$6.39M |
|
428
Compass Therapeutics
CMPX
$344M
| $7.13M | ﹤0.01% |
+1,348,259
| New | +$7.78M |
|
429
Diamondback Energy
FANG
$57.1B
| $7.1M | ﹤0.01% |
35,891
-500
| -1% | -$85K |
|
430
Exelixis
EXEL
$13.3B
| $7.07M | ﹤0.01% |
164,949
+11,225
| +7% | +$483K |
|
431
Pebblebrook Hotel Trust
PEB
$2.15B
| $7.02M | ﹤0.01% |
556,203
+40,829
| +8% | +$501K |
|
432
iShares ESG Aware 1-5 Year USD Corporate Bond ETF
SUSB
$1.3B
| $6.96M | ﹤0.01% |
277,662
+18,224
| +7% | +$459K |
|
433
Acadia Realty Trust
AKR
$3.09B
| $6.92M | ﹤0.01% |
361,828
-1,191
| -0.3% | -$24.3K |
|
434
STAG Industrial
STAG
$7.38B
| $6.89M | ﹤0.01% |
190,932
+7,692
| +4% | +$292K |
|
435
First Industrial Realty Trust
FR
$8.73B
| $6.86M | ﹤0.01% |
118,594
+9,798
| +9% | +$583K |
|
436
Vanguard Morningstar Total Stock Market ETF
VTI
$660B
| $6.83M | ﹤0.01% |
21,302
+4,482
| +27% | +$1.5M |
|
437
State Street SPDR S&P Capital Markets ETF
KCE
$456M
| $6.79M | ﹤0.01% |
49,343
-1,441
| -3% | -$213K |
|
438
United Parcel Service
UPS
$88.6B
| $6.69M | ﹤0.01% |
67,961
+10,999
| +19% | +$1.18M |
|
439
iShares Russell 1000 Growth ETF
IWF
$121B
| $6.64M | ﹤0.01% |
62,332
+14,096
| +29% | +$1.6M |
|
440
Hexcel
HXL
$7.79B
| $6.55M | ﹤0.01% |
80,983
+5,457
| +7% | +$460K |
|
441
Cogent Biosciences
COGT
$6.65B
| $6.44M | ﹤0.01% |
167,412
+119,498
| +249% | +$4.41M |
|
|
SFBS
442
ServisFirst Bancshares
SFBS
$4.89B
| $6.42M | ﹤0.01% |
88,202
+12,641
| +17% | +$1M |
|
443
CVS Health
CVS
$133B
| $6.35M | ﹤0.01% |
88,392
-3,998
| -4% | -$308K |
|
444
CBRE Group
CBRE
$42.5B
| $6.33M | ﹤0.01% |
46,735
-16
| -0% | -$2.43K |
|
445
Fidelity MSCI Consumer Discretionary Index ETF
FDIS
$1.68B
| $6.24M | ﹤0.01% |
66,957
-463
| -0.7% | -$46.4K |
|
446
Cohen & Steers
CNS
$4.23B
| $6.03M | ﹤0.01% |
96,398
-12,953
| -12% | -$845K |
|
447
iShares MSCI Australia ETF
EWA
$1.39B
| $6.02M | ﹤0.01% |
216,991
-390,006
| -64% | -$11M |
|
448
IBM
IBM
$211B
| $5.98M | ﹤0.01% |
24,688
+4,341
| +21% | +$1.17M |
|
449
Nurix Therapeutics
NRIX
$2.41B
| $5.96M | ﹤0.01% |
+384,831
| New | +$6.38M |
|
450
Vericel Corp
VCEL
$2.35B
| $5.96M | ﹤0.01% |
185,337
-2,279
| -1% | -$80.9K |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.